title: Clinical application of bone marrow implantation in patients with arteriosclerosis obliterans, and the association between efficacy and the number of implanted bone marrow cells.
abstract: BACKGROUND
  There have been a number of recent reports on the use of autologous bone marrow implantation (BMI) in the treatment of peripheral arterial disease, with a clinical response rate of approximately 70%. However, the factors that influence efficacy have not yet been clarified. We have analyzed the relationship between the number of implanted bone marrow cells and the clinical efficacy of BMI.
  
  
  RESULTS
  Eight patients with arteriosclerosis obliterans were treated with BMI. Bone marrow was aspirated from the ilium (500-1,000 ml), the mononuclear cells were separated and then were implanted. The clinical effectiveness of BMI was evaluated by assessing changes in the ankle-brachial pressure index (ABI) and the transcutaneous oxygen pressure (TcO2) between the pre-treatment baseline, with follow-up testing at 4 weeks. These changes were defined as DeltaABI and DeltaTcO2. The mean number of CD34-positive cells was 1.04+/-0.60 x10(6) /kg body weight. There was a strong correlation between the number of CD34-positive cells and DeltaABI (r=0.754, p=0.028).
  
  
  CONCLUSIONS
  It is likely that the number of implanted CD34-positive cells is one of the primary factors that influence the clinical efficacy of BMI.
authors.affiliation: Division of Cardiology, Niigata University Graduate School of Medical and Dental Sciences, Asahimachi, Niigata-City, Niigata, Japan.
authors.forename: Takashi
authors.initials: T
authors.lastname: Saigawa
authors.forename: Kiminori
authors.initials: K
authors.lastname: Kato
authors.forename: Takuya
authors.initials: T
authors.lastname: Ozawa
authors.forename: Ken
authors.initials: K
authors.lastname: Toba
authors.forename: Yashiro
authors.initials: Y
authors.lastname: Makiyama
authors.forename: Shiro
authors.initials: S
authors.lastname: Minagawa
authors.forename: Shigeo
authors.initials: S
authors.lastname: Hashimoto
authors.forename: Tatsuo
authors.initials: T
authors.lastname: Furukawa
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Nakamura
authors.forename: Haruo
authors.initials: H
authors.lastname: Hanawa
authors.forename: Makoto
authors.initials: M
authors.lastname: Kodama
authors.forename: Nobuhiko
authors.initials: N
authors.lastname: Yoshimura
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Fujiwara
authors.forename: Osamu
authors.initials: O
authors.lastname: Namura
authors.forename: Masakazu
authors.initials: M
authors.lastname: Sogawa
authors.forename: Jun-ichi
authors.initials: J
authors.lastname: Hayashi
authors.forename: Yoshifusa
authors.initials: Y
authors.lastname: Aizawa
mesh_terms: D000368:Aged; D015901:Angiography, Digital Subtraction; D000842:Ankle / Q000098:blood supply; D018952:Antigens, CD34 / Q000032:analysis; D001162:Arteriosclerosis Obliterans / Q000097:blood / Q000000981:diagnostic imaging / Q000503:physiopathology / Q000601:surgery*; D001785:Blood Gas Monitoring, Transcutaneous; D001794:Blood Pressure; D001854:Bone Marrow Cells / Q000276:immunology; D016026:Bone Marrow Transplantation; D001916:Brachial Artery / Q000503:physiopathology; D002452:Cell Count; D003097:Collateral Circulation; D005260:Female; D006801:Humans; D007866:Leg / Q000098:blood supply; D008297:Male; D008875:Middle Aged; D018919:Neovascularization, Physiologic; D016896:Treatment Outcome; D014463:Ultrasonography
chemical_list: D018952:Antigens, CD34